Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set
Open Access
- 13 January 2021
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (5) , 1243-1246
Abstract
A number of new treatments have been approved for patients with multiple myeloma (MM) and the survival of patients continues to improve. However, discrepancies in outcomes of clinical trials and th...Keywords
Funding Information
- Takeda
- National Institute for Health Research University College London Hospitals Biomedical Research Centre
This publication has 9 references indexed in Scilit:
- Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myelomaAnnals of Hematology, 2020
- The Magic of Randomization versus the Myth of Real-World EvidenceNew England Journal of Medicine, 2020
- High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myelomaBlood, 2019
- Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient ProgramPathology and Oncology Research, 2019
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingBlood Cancer Journal, 2018
- Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating OutcomesClinical Lymphoma Myeloma and Leukemia, 2017
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trialLeukemia, 2017
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016